Mylan Launches Generic Crestor® Tablets

USA Profile Username: jon@newsinnovations.com / edit profile Mylan Launches Generic Crestor® Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, July 20, 2016 HERTFORDSHIRE, England and PITTSBURGH, July 20, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Rosuvastatin Calcium Tablets, 5 mg, 10 mg, 20 mg and 40 mg, which is a generic version of AstraZeneca's Crestor®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Rosuvastatin Calcium Tablets are used in combination with diet for the treatment of high triglycerides (hypertriglyceridemia) in adults. Rosuvastatin Calcium Tablets, 5 mg, 10 mg, 20 mg and 40 mg, had U.S. sales of approximately $6.7 billion for the 12 months ending May 31, 2016, according to IMS Health. Currently, Mylan has 245 ANDAs pending FDA approval representing $101.6 billion in annual brand sales, according to IMS Health. Forty-one of these pending ANDAs are potential first-to-file opportunities, representing $30.8 in annual brand sales, for the 12 months ending December 31, 2015, according to IMS Health. Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,400 generic and branded pharmaceuticals, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in approximately 165 countries and territories. Our global R&D and manufacturing platform includes more than 50 facilities, and we are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com. Logo - http://photos.prnewswire.com/prnh/20140423/77793 SOURCE Mylan N.V. CONTACT: Nina Devlin (Media), 724.514.1968; or Kris King (Investors), 724.514.1813 Web Site: http://www.mylan.com Follow Us To change the settings for your profile(s) or email delivery, go to https://prnmedia.prnewswire.com/profile/?action=editProfile and select the profile you would like to edit. You can select the industries, subjects, languages, geographical areas, companies, delivery options and delivery frequencies of your choice. In addition to current press releases, you can also find archived news, corporate information, photos, tradeshow news and much more on the PR Newswire for Journalists website: https://prnmedia.prnewswire.com To contact us, email: mediasite@prnewswire.com Please do not reply to this email; this is an automatically generated message. Copyright © PR Newswire Association LLC. All Rights Reserved. A UBM plc company. Our mailing address is: 350 Hudson Street, Suite 300 New York, NY 10014-4504